Search

Your search keyword '"Pellicanò, Giovanni Francesco"' showing total 133 results

Search Constraints

Start Over You searched for: Author "Pellicanò, Giovanni Francesco" Remove constraint Author: "Pellicanò, Giovanni Francesco"
133 results on '"Pellicanò, Giovanni Francesco"'

Search Results

1. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

2. Incident diabetes in course of antiretroviral therapy

3. Viro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort.

4. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study

5. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study

8. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

9. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

10. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir

11. Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

12. Incident diabetes in course of antiretroviral therapy

13. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

14. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study

15. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study

16. Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

17. SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio.

19. Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

20. Efficacy of COVID-19 Vaccination in People Living with HIV: A Public Health Fundamental Tool for the Protection of Patients and the Correct Management of Infection

21. ALIMENTAZIONE, AMBIENTE E SALUTE

22. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.

25. The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile

26. Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

27. Pulmonary Kaposi Sarcoma without Respiratory Symptoms and Skin Lesions in an HIV-Naïve Patient: A Case Report and Literature Review

29. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study

30. Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort

31. Pre-cART inflammation, microbial translocation and Long-Term probability of clinical progressione in people living with HIV

33. Trajectories of CD4 + /CD8 + T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.

34. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

35. Enhanced metabolic health and immune response with bictegravir/emtricitabine/TAF: Insights from a 96‑week retrospective study.

38. Factors Associated With Weight Gain in People Treated With Dolutegravir

39. Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study

40. Factors Associated With Weight Gain in People Treated With Dolutegravir

41. Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare

42. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.

43. Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare

44. HIV‐associated psoriasis: Epidemiology, pathogenesis, and management

45. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection.

48. Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review

49. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.

Catalog

Books, media, physical & digital resources